RG6382 / Roche - LARVOL DELTA

Roche may have scrapped work on a T-cell engager (TCE) for lupus… (FierceBiotech) - "As part of a wider pipeline clearout disclosed during Roche’s second-quarter earnings results released July 23, the Swiss pharma revealed that it had stopped work on RG6382, a T-cell-engaging bispecific antibody targeting CD19 and CD3. The company had been evaluating the therapy in an ongoing phase 1 open-label study of patients with systemic lupus erythematosus (SLE)...Roche spokesperson explained to Fierce this morning that after reviewing the data to date, 'it has become clear that this molecule does not have the requisite characteristics to move forward in this indication.'...'Since SLE was the lead indication for this asset, this discontinuation marks the termination of its development,' the spokesperson added."

Discontinued • Systemic Lupus Erythematosus

A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=70 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Recruiting ➔ Active, not recruiting

Enrollment closed • First-in-human • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Characterization of RO7507062, a CD19-Targeting T-Cell Bispecific Antibody (CD19TCB), and Design of Its Ongoing Phase 1 Trial in Systemic Lupus Erythematosus (ACR Convergence 2024) - P1 | "RO7507062 was designed as a next generation off-the-shelf B-cell depleter dedicated for patients with autoimmune diseases. A first-in-human study in patients with SLE is ongoing."

P1 data • B Cell Non-Hodgkin Lymphoma • Hematological Disorders • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lupus • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Systemic Lupus Erythematosus • CD20 • CD34

CHARACTERIZATION OF RO7507062, A CD19-TARGETING T-CELL BISPECIFIC ANTIBODY (CD19TCB), AND DESIGN OF A PHASE 1 TRIAL IN SYSTEMIC LUPUS ERYTHEMATOSUS (EULAR 2024) - P1 | "RO7507062 was designed as a next generation off-the-shelf B-cell depleter dedicated for patients with autoimmune diseases. A first-in-human study in patients with SLE is ongoing."

P1 data • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lupus • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Systemic Lupus Erythematosus • CD20 • CD34

A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=70 | Recruiting | Sponsor: Hoffmann-La Roche | Not yet recruiting ➔ Recruiting

Enrollment open • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=70 | Not yet recruiting | Sponsor: Hoffmann-La Roche

New P1 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus